OUTPERFORM: We initiate coverage on Immunovia with a stepwise valuation approach. For 2019, we see a reasonable valuation range between SEK 220-240 per share suggesting 28-40% upside to the current share price. For 2020, we see a range between SEK 270-300 per share suggesting 57-75% upside to the current share price. For 2021, we see a reasonable valuation range between SEK 390-440, suggesting 127-156% upside to the current share price.
Novel diagnostic product platform with a first focus on pancreas cancer
Immunovia is a Swedish-based diagnostic company in late-stage development for products for early detection of diseases within the oncology and autoimmune areas, with a primary target on early detection of pancreas cancer. The company’s management team has extensive diagnostic company background, including GE Healthcare and Dako (aquired by Agilent).
Marketing material commissioned by Immunovia AB